How to Cite:
Al Otaibi, S. G., Anazi A. A. M., Nahis Bin Barrak, T. M., Al-Rashudi, K. A. R. S., Alqhoson, A. I., Alshahrani, A. A., Alfaleh, T. A., Aldosari, Areej O., Alazmiy, Barakat S., & Alanizi, Anoud S. (2024). The role of pharmaceutical laboratories in drug development and quality control. *International Journal of Health Sciences*, *8*(S1), 1979–1994.
https://doi.org/10.53730/ijhs.v8nS1.15463

The role of pharmaceutical laboratories in drug development and quality control

Mr. Sanytan Ghazy Al Otaibi
KSA, National Guard Health Affairs

Ahmad Ayad M Anazi
KSA, National Guard Health Affairs

Talal Muhammad Nahis Bin Barrak
KSA, National Guard Health Affairs

Khaled Abdul Rahman Suleiman Al-Rashudi
KSA, National Guard Health Affairs

Abdulelah Ibrahim Alqhoson
KSA, National Guard Health Affairs

Abdullah Ali Alshahrani
KSA, National Guard Health Affairs

Tariq Abdulaziz Alfaleh
KSA, National Guard Health Affairs

Areej Obaid Aldosari
KSA, National Guard Health Affairs

Barakat Shumailan Alazmiy
KSA, National Guard Health Affairs

Anoud Saud Alanizi
KSA, National Guard Health Affairs

***Abstract*---Background** :Pharmaceutical laboratories have social significance and their duty involves essential involvement in drug development as well as compliance with quality parameters for the betterment of patient status. **Aim** :Analytical techniques and innovations, quality control in drug development and pharmaceutical

International Journal of Health Sciences E-ISSN 2550-696X © 2024.
Corresponding email: *akk29337@gmail.com*
Manuscript submitted: 01 Jan 2024, Manuscript revised: 09 Jan 2024, Accepted for publication: 15 Jan 2024

laboratories are what this particular study seeks to bring to the forefront. **Methods:** There is a need to have some literature review and previous studies for determination of drug development stages, preclinical analysis and the control of quality. **Results:** Labs improve on the effectiveness of a drug through quality mechanisms, advancement in technology and other legal measures. **Conclusion:** Pharmaceutical laboratories play a central role to facilitate safe and effective drugs and other anticipations in the future developments of medicine.

***Keywords*---**Pharmacology, managed care, pharmaceuticals production and testing, analytical methodology, pharmaceuticals advances**.**

Introduction

These are essential facilities in the discovery of drugs, development and quality control of products that are essential in the protection of health all over the world. These laboratories are involved in determining the safety, efficacy and probably the reliability of any anti-therapeutic compounds starting from the time they are identifiably to the time synthetically compound is produced. Drug development process that ranges from preclinical stage to commercialization of the drug requires creativity and adhere to regulatory requirements. Analyzing the specific and intricate diseases, the pharma field has reached significant growth due to the modern analytical methodologies and breakthrough laboratory techniques. This paper aims at identifying the complex roles of pharmaceutical laboratories, and among them include; the services of preclinical testing, quality assurance activities, various approaches to analysis, legal requirements and the consequences of advancements made on the effectiveness of laboratories on drug effectiveness.[1,2]

Overview of Pharmaceutical Laboratories

Pharmaceuticals laboratories are centers of scientific innovation focused on the analysis, synthesis, and experiments of drugs with special reference to their safety, efficacy and quality. These laboratories form the base of any pharmacy company of any type and include all the functions from the basic research to the quality check. Essentially, pharmaceutical laboratories represent strategic centers in which professionals –scientists and researchers – develop new molecules, formulations, and methods of drug delivery. These chemical laboratories are well outfitted with modern technology and equipment that allow methodical examination of chemical compounds, biological agents and drug formulations.[3,4,5]The structure of pharmaceutical laboratories is also diverse due to their versatility of their functions and tasks. R&D laboratories for drugs are involved in the first stage of drug discovery, picking out drug leads and initial toxicity testing. The analytical laboratories focuses on assessment of raw materials, work in progress and finished products to meet regulatory requirements. Every step of production must be checked by a QC laboratory to ensure that the product under test complies with the required specifications and

is not contaminated.[6,7] In addition, stability testing laboratories also determine the shelf life of the pharmaceutical products based on environmental operating conditions.[8]

Pharmaceutical and laboratories also follow strict rules and regulation set by these controlling bodies like FDA, EMA and WHO. These guidelines supplement the handling of lab procedures and reporting procedures, testing procedures to ensure accuracy of results as well as safety of an off type drug to be administered to the public. Due to high-end equipment like High-Performance Liquid Chromatography (HPLC), mass spectrometry and molecular modeling, the pharmaceutical laboratories have further asserts their efficiency in speed with high accuracy. Ongoing competition fosters the growth of new therapies; pharmaceutical laboratories adapt to this need, using new areas such as biotechnology, nanotechnology, or artificial intelligence to advance new drug development and quality control.[9,10]

Stages of Drug Development

The process of drug development in an intricate one that may be defined as the process of turning an inspirational scientific idea into a safe and efficient medication for patients. It encompasses several important steps here all of which are composed for the purpose of safety, efficacy and quality of the final pharmaceutical product. One of the process is the **drug discovery** through which scientists find potential medicines for the disease by addressing certain biological activities connected with the specific disease. This step usually has testing of thousands of chemical substances, bioinformatics assistance, and comprehensive knowledge of the illness to trim the field. Once a lead compound is chosen it is then optimized to provide increased therapeutic activity whilst at the same time reducing toxicity as much as possible.[11,12] The next stage, preclinical stage checks the safety, kinetics, and dynamics of the drug using cell and animal models. This stage is important for determining effect of the drug on biological systems, how it is absorbed or distributed, how it gets metabolized and whether it is toxic. In this case, the preclinical outcomes positive, the drug developer files an Investigational New Drug (IND) application intending to commence human trials after the approval by concerned authorities for instance the FDA.[13,14] Once approved for clinical testing, the drug goes through the latter stage called clinical trials and this takes three phases only. The first, or first-in-human, trials of a drug call Phase I and include only 20 to 100 healthy volunteers or patients and are aimed at assessing safety, tolerance and the range of doses. Phase II tends to increase the number of participants in addition to comparing the efficiency of the drug when used to treat the focal pathology. Therefore, Phase III trials include relatively unsophisticated but representative populations in evaluating the drug efficacy and the occurrence and severity of side-effects as well as the drug's superiority to other treatments. The results obtained from those trials are then submitted in what is referred to as New Drug Application (NDA) or any other similar submission.[15] After approval, the drug moves to the marketed phase during which it is produced, sold and dispensed to the populace. The drug is again overseeed through post marketing surveillance (Phase IV) to see if there are any side effects which can be observed in patients but may not have been registered during the pre marketing studies. They also determine the drug's

efficiency in daily practice and can result in new areas of application or the administration change.[16] All phases of clinical development for drugs are regulated to the highest standards to minimize risk to patients and to guarantee product quality. The process is complex and expensive it may take a decade or more and cost billions of dollars to deploy a single product on the market. However, the opportunities of using biotechnology, genomics, and data analysis in drug development are progressing rapidly, which fosters the idea of developing customized drugs improving the patient's condition and meeting the unmet needs. The high level of these stages increase to show the pharmaceutical industries world practice of developing safe and effective drugs for the human population.[17] .

The Laboratories in the Conduct of Preclinical Testing

Laboratories in Preclinical Testing Preclinical studies are considered to be a very important part of the drug development process because they set the ground work on how safe and/or effective a certain drug candidate may be to man. A number of experiments are carried out at this stage by laboratories which provide the essential data for a drug to progress through the clinical trial stage. Preclinical testing typically involves two main types of studies: In vitro or test tube or cell culture [Clive 2004] and In vivo or animal [Kemp 1999]. They are intended to determine the drug's efficacy-safety profile, the absorption, distribution, metabolism, and excretion profiles, and the drug effect-biological system response relationship. These generated during this phase are very essential in risk assessment as well as in formulation of the drug. In vitro studies on drug metabolism involved in laboratories which are concerned with the evaluation of the drug on enzyme receptors or cell line both racially and in terms of extent of metabolism. These prove effective in identifying the way in which the drug works and the strength of the drug at the molecular level. Bioassays such as high through put screening, cell proliferation assay and receptor binding assay are widely used to determine presence and potency of the drug. Also, in vitro toxicological assays assess the ability of a compound to/or induce cytotoxicity, genotoxicity, or any other toxicities. This stage gives the first idea of the drug's therapeutic ratio which is the ratio between the amount of the drug that is toxic and the amount that is beneficial. New innovative systems like 3D cell cultures, and the organ-on-a-chip systems are common nowadays in preclinical laboratories due to their better accuracy in predicting human responses.[18,19]

In vivo experiments are carried out to support in vitro results with an evaluation on the impact of the drug in a living organism. These studies are important for determining of pharmacokinetics, including the absorption, distribution, metabolism, and excretion, and pharmacodynamics factors including hepatotoxicity, nephrotoxicity, cardiotoxicity, and neurotoxicity. Animal models that offer features of human physiological and disease status are employed in laboratories to determine the therapeutic efficacy and toxicology of the drug. For instance, whereas simple extrapolations of toxicities in rodents, particularly the rat model for first screenings, may be used, progressively more complex tests might require larger animal models. IERA's like the FDA need information from such research to determine whether a drug can be taken to the human beings for use. Any laboratory carrying out in vivo studies should only do so once they have

complied with laid down ethical standards and the GLP. Apart from safety and efficiency, research laboratories play the role of formulation development of the drug during the preclinical trials. They concern themselves with activities such as solubility, stability and bioavailability profiles so as to enable the drug to be delivered to the target site. Analytical laboratories are involved in this process by devising procedures for determining the concentration of the drug in biological matrices and for searching for impurities or degradation products thereof. Concisely, laboratories play string significant role in preclinical research, since the data obtained in them are crucial to pass on to the human clinical trials. Thus, besides the protection of the interests of trial participants, such work eliminates delays in further trials and helps avoid late-stage failures. Thus, preclinical laboratories as the laboratories that unite high-tech technologies, the strict policy of experimentation, and ethical principles, act as key infrastructure for drug development from the stage of discovery to clinical implementation.[20,21,22]

Process Quality Assurance in Drug Production

Quality control which is often referred to as QC is widely used in the pharmaceutical manufacturing industry and is critical in assuring that USP < |Human| Quality products are delivered to patients. In QC activity, the tests are carried out throughout the production cycle beginning from procurement of raw materials to the launching of the finished product in the market. This systematic approach enables the manufacturers to adhere to the law provisions, mitigate and have a sound reputation among the consumers. QC activities are coordinated within laboratories in order to undertake complex analytical methods, procedures, and strict rules to guarantee that delivered products meet specified requirements.[23,24] The first activity of QC involves Checking physical and chemical aspects of the raw materials used in the production of drugs. Cooperating to begin testing the batch of raw material which view the purity, the potency and the inhibitor of impure material. Even small differences in the specificity of reagents used can produce critical problems during the manufacturing process and affect the quality and safety of the end product. Methods of raw material control include high-performance liquid chromatography (HPLC), gas chromatography (GC), and Fourier-transform infrared spectroscopy (FTIR). Further, microbial analysis is carried out in order to identify microbial growth and disinfect them as they prove very dangerous to human health.[25,26]

Preliminary in manufacturing inspection and test (MIT, there is in-process quality control (IPQC) that guarantees that various processes in production are standard and meet the right quality. This calls for the control of certain manufacturing variables ranging from temperature, pressure, solution pH and mixing time amongst others to help replicate the manufacturing process. Sampling of intermediate products and testing show deviations immediately so as to correct them before they affect the final product.[27,28]For example, during tablet production, some of the IPQC may checks weight variation, hardness, and disintegration to ensure the batches are manufacture with the right standard.[29] There are many tests that are conducted on the final product to ensure that it meets certain standard and is fit to be released on the market.. It includes physical, chemical and microbiological analysis to affirm product's identity, potency, purity and stability. One such stability test, stability testing, plays an

important role in identifying exactly how long the particular drug will last and under what conditions it will need to be stored. These tests mimics different environmental conditions including temperature, humidity, and exposure to light with a view to comparing the properties of the drug at different times. In case of packaging materials also their performance is checked in terms of how effectively they shield the product from environmental influences. In addition, the sterility testing is required to assure the injectable drug or any other sterile product is not contaminated with microbes.[30,31]

It Is very important in QC of pharmaceutical manufacturing that they have to strictly adhere to regulatory compliance. Manufacturers are expected to follow GMP as well as regulatory authorities' guidelines from FDA, EMA as well WHO. Compliance with these regulations requires documentation of all QC activities such as tests to be carried out, tests results and actions to be taken in case of non conforming batches. Accreditation of quality control laboratories also require the instrumentation to be calibrated, the methods used be validated and personnel skilled in analysis. However, the current and more developed QC includes a cascade of tests that involves use of equipment's and automations for fast and accurate information. Innovations include; UV/Visible spectroscopy, mass spectrometry, NMR and real time monitoring that facilitates speedy and comprehensive formulation characterization.[32,33]The use of digital tool like – LIMS improves the data management and its traceability in the lab. Lastly, it concerning quality control process is remarkable that quality control processes in the manufacturing of pharmaceutical products are badly needed in order to ensure that patient get quality medications which are both safe as well as effective. As a result of executing these tests according to high standards of quality and incorporating state-of-the-art technologies into the work of a QC laboratory, the public's health and the ethical character of the pharmaceutical and biopharmaceutical industry continue to be protected.[34,35,36]

Northern Ireland companies and organizations involved in drug development have applied several analytical techniques in their drug development process

The main analytical methods have important roles throughout the drug development process to contribute valuable data on safety, efficacy, and quality of pharmaceutical products. These techniques are used at every stage of the drug development process including during the identification of likely drug aspirants and during the conduct of quality checks. They assist the researchers in describing the APIs, enhancing formulation of dosage forms, assessing the pharmacokinetics and the regulatory standards.[37] Pharmaceutical industry, seeks extensive, an accurate structural elucidation, quantification, and comprehensive analysis of chemical substances, for which, new scientific approaches of instrumental analysis have greatly transformed the field. The most popular technique in drug development is high-performance liquid chromatography (HPLC). This method can effectively isolate, categorize and quantify components of a mixture and as such is very useful in determining the APIs and general impurities. Analytical HPLC is employed for quantitative analysis of drug content, purity as well as confirming potency of drugs, monitoring stability of drugs and to validate manufacturing processes. Derivatives

like reverse phase HPLC and UHPLC features higher sensitivity and expedited run times thereby expanding the drug development process efficiency. Other important form of chromatographic analysis is the gas chromatography (GC) used for determination of volatile and semi-volatile samples. GC is especially used in the analysis of the impurities and degradation products of pharmaceutical compounds.[37,38,39]

Another essential technology is mass spectrometry (MS); this technology is commonly pairs with chromatography for molecular profiling. In comparison, MS offers the exact molecular weight data in the identification of the drug compounds and their metabolites. It also plays a role of identifying very small concentration of impurities or contaminants in the product hence it is important in assortment of safety. Some of the most frequently applied methods are chromatographic techniques carried out using liquid chromatography interfaces with the mass spectrometer to from LC-MS and gas chromatography interfaces with the mass spectrometer to form GC-MS, and these bioanalytical techniques are widely used in bioavailability/ bioequivalence assessment and pharma kinetic metabolism. FTIR spectroscopy is also widely used in drug development to determine the presence of so-called functional groups and to describe chemical bonds that are essential for structural elucidation.[38,39]

Another complementary method frequently employed for declaration of molecular structure and dynamic nature of drug compounds is nuclear magnetic resonance (NMR) spectroscopy. NMR is important to quite a number of aspects in the quality control of APIs and intermediates because it reveals an understanding of the positional usefulness of atoms within a compound. Also, UV-Visible Spectrophotometry is the most common technique for determining drug concentrations and observing how the drug responds to light exposure; vital for stability testing and photostability assessment.[40,41] In the specialized areas involving biological drugs and complex formulations, critical instrumental methods are capillary electrophoresis and X ray diffraction analysis. CE is more suitable for the separation of biomolecules such as peptides, proteins, and nucleic acids, X-ray crystallography is appropriate for determining the molecular shape or conformation of a molecules including drug-receptor interactions. In the case of nanomedicine and advanced drug delivery system particle size, distribution, and morphology are measured using dynamic light scattering (DLS) and scanning electron microscopy (SEM).[42]

Quality assurance and control during drug manufacturing also involve a lot of analytical methods. Dissolution testing for instance determines a drug solubility rate in a given medium or media solubility so as to determine its ability to deliver the active pharmaceutical ingredient at a constant rate. In the same manner microbial analytical techniques are used to determine sterility and microbial count mostly in parenteral products and other sterile products such as injectable drugs.[43,44] The use of other technologies including hyphenated techniques, automation and artificial intelligence in chemical analysis continues to boost other analytical methods in drug development. That's the reason LC-MS/MS and GC-MS/MS are capable of determining multiple components of a sample at once and such methods exhibit high sensitivity and selectivity. Automations and robotic operations in laboratories have enhanced repeatability and shortened the

time needed to complete complicated tests. Also, the process of interpreting large amounts of analytical data has now been handled through AI algorithms hence speeding up decision making and innovation in drug development.[45,46] Thus, analytical methods are in the center of drug creation, stressing product dependability and uniformity. These techniques help in deeming an understanding of the composition and structure of drugs as well as the behaviour to obtain safe and effective high quality drugs. In effective years to come, analytical methods will be at the forefront not only due to the advancement of technology.[47,48]

Regulatory Compliance and Standards in Quality Control

GMP and FDA requirement are the pillars of Quality control (QC) in the production of pharmaceuticals. These requirements aim to ensure that often prescribed drugs are safe, effective and have quality for the patients.[49,50] There are guidelines from recognized agencies like US FDA, European Medical Agency and the World Health Organization, which offer all-encompassing checklists that touch every step in production process of pharmaceutical, right from sourcing of raw material to the final point of release of the product. The pharmacovigilance regulatory processes are not only mandatory, but also serve a critical purpose of preserving the reinforcements of the industry and the health of the populace for everyone active in the business of drug manufacturing and distribution.[51,52] Among the major standards of the pharmaceutical regulatory system there is Good Manufacturing Practices (GMP). These guidelines describe the minimum expectations about manufacturing procedures, facilities, equipment, and people required for manufacturing of quality drugs. Compliance with GMP standards means that the pharmaceutical company has to implement a sound QC system which controls and checks every process. For instance, the raw material should undergo identification, purity and potency tests before being used while every equipment used in production should be kept on check against any drift that may affect the quality of the final product. Documentation is equally important while implementing GMP with records to support every batch prepared and produced. However, if batch numbers are used they make it easier for backtracking and help in investigations in the event of a recall or untoward incident.[33]

Ref: GMP and Good Laboratory Practices (GLP) are the two important pillars upon which QC is founded to uphold standard operations of analytical and testing laboratories. GLP is especially aimed at guaranteeing that all preclinical studies including chemical and microbiological tests are performed according to the protocols that would allow for the production of objective and replicable results. Any procedures conducted within laboratories should be accurate and with proper equipment, all personnel must conduct themselves with competence. Special concern with GLP is most especially relevant in generation of data that will be presented to the regulatory bodies during the approval of the drug.[34,35] Regulatory agencies also require compliance to pharmacopoeia requirements, which are procedures that were set down to conduct testing on drugs consumables to determine their quality. The main global pharmacopoeias are United States Pharmacopoeia (USP), European Pharmacopoeia (Ph. Eur.), and British Pharmacopoeia (BP) and the specifications relating to the substances, other than finished products, are rather specific. These standards address many

factors of identity, purity, potency, dissolution, and sterility and are revised from time to time to reflect more advanced methods of analyses as well as new safety issues. Requisite conformities to pharmacopoeia standards are important in ascertaining that the drugs in the production line are compliant to the current standards as well as the market forces.[36,37]

The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)** has provided further simplification of the procedures of QC at international level other than the national and regional legislations. The ICH also produces harmonized work on many subjects of drug development and manufacturing, such as stability testing, impurity testing, and methods development. These guidelines help ensure that pharma companies overcome varies global regulatory hurdles by distilling regulatory requirements to a common set. For example, ICH Q10 guideline on pharmaceutical quality systems provides guidance on risk based approach to quality management over a product, so that the systematic management of risks can help the manufacturers to identify crucial quality characteristics of a product and thus it reduces the probability of failure of that product.[38] Like any other country, technological utilization and quality management system in QC are also governed by some certain regulations. Increased process understanding and control require methodology like Process Analytical Technology (PAT) and Quality by Design (QbD), which are actively recommended by regulatory agencies. These approaches allow producers to continually measure important quality characteristics during production, and minimize the need for a solely test-based quality control. Furthermore, electronic systems including Laboratory Information Management Systems (LIMS) and electronic batch records enhance data flow, and trace abilities consequently supporting compliance processes. Litigation or fines are imminent, along with multiple other realized disadvantages to the product, organization, and customer base should revelations of non-compliance occur or fail to occur intentionally. Therefore, pharmaceutical industries spend generous amount of money, time and effort in setting up and implementing efficient and effective QC systems that are compliant to regulations. From the regulatory aspects, Periodic examination and assessment by the relevant authorities guarantee compliance by the manufacturers besides enhancing improvement in their business. As well as the traditional tools and techniques for QC, the Inspections involve auditing on the quality culture within the company.[39,40] Thus, it is obligatory for various pharmaceutical products to meet all the required norms and guidelines basic to regulatory compliance and ant quality standards. Compliance with GMP, GLP, pharmacopoeial standards, and international guidelines is the vehicle through which pharmaceutical business can prove the highest level of quality and compliance with various regulatory requirements. These activities do not only guard the health of the public but also promote development and confidence in the drug sector for the advantage of sufferers globally.[41]

Innovation in the Laboratory and its influence on efficacy of drugs

Pharmacological advancement resulting from research and development in the chemical laboratories of the pharmaceutical companies has brought dramatic change to the outcomes of drug delivery, medicine making, testing and fine-

tuning for use. Modern technologies and methods have allowed for better development of targeted drugs, drugs that affect the disease process without having many negative effects on the patient. These innovations have not only reduce time taken in developing new drugs but also helped in achievement of goal of efficient personalized medicine.[42,43]One area where changes in the laboratory play a critical role in affecting efficacy of the drug is drug discovery and design. Some of the testing approaches for example the high throughput screening (HTS) and computational drug designing have made it easier to find probable drug targets. Normal HTS involves screening of large aggregates of compounds against biological targets for a short period employing automated systems in order to come up with the molecules with the greatest therapeutic utility. While, computational drug design uses molecular modeling and simulations to estimate how the drug will respond with its target at molecular level. Combined, these approaches have enhanced the potentials of drug design by making these molecules more accurate in terms of achieving the intended pharmacologic effects and reduced probability of binding to unintended targets. [44]

The application of biotechnology and genomic tools also brought new horizons in laboratory advances remaining in its basis, however. Genome editing through CRISPR-Cas9 and other molecular tools enables disease genetic predisposition studies of Laboratories can determine those genes or pathways responsible for the disease process and thus design treatments that will focus on the cause of the condition. These advancements have also birthed new drug classes including monoclonal antibodies, gene-tailored therapies as well as small interfering RNA (siRNA. These therapies present very specific modes of working, and frequently present higher effectiveness for diseases that were typically tricky to manage in the past, including cancer, autoimmune diseases, and rare genetic disorders. [45] From the analysis techniques one can also note that improvements have advanced in designing an efficient drug since analysis offers detailed information on the physical, chemical and biological characteristics of the drug. Analytical tools such as mass spectrometry, Nuclear magnetic resonance (NMR) spectroscopy ,X-ray crystallography help scientist to describe a drug molecule right from the atomic level. For instance, structural biology platform assist scientists in designing new drugs and improving the drug target's affinity and potency.[46]

Conclusion

Pharmaceutical laboratories stand at the forefront of modern medicine, driving advancements that have revolutionized drug development and quality control. Through meticulous preclinical testing, rigorous compliance with regulatory standards, and the use of cutting-edge analytical techniques, laboratories ensure that medications meet the highest safety and efficacy standards. Innovations in laboratory technologies have further transformed the pharmaceutical landscape, enabling the development of targeted therapies, improved drug delivery systems, and personalized medicine approaches. The impact of these innovations extends beyond individual drugs, fostering trust in the pharmaceutical industry and enhancing global healthcare outcomes. As science and technology continue to

advance, the role of pharmaceutical laboratories will only grow in significance, paving the way for even more transformative breakthroughs In medicine.

References

1. Amadi, C., & Tsui, E. K. (2019). How the quality of essential medicines is perceived and maintained through the pharmaceutical supply chain: A perspective from stakeholders in Nigeria. Research in Social and Administrative Pharmacy, 15(11), 1344-1357.
2. Cyr, M. E., Etchin, A. G., Guthrie, B. J., & Benneyan, J. C. (2019). Access to specialty healthcare in urban versus rural US populations: A systematic literature review. BMC Health Services Research, 19(1), 1-17.
3. Ekeigwe, A. A. (2019). Drug manufacturing and access to medicines: The West African story. A literature review of challenges and proposed remediation. AAPS Open, 5(1), 3.
4. Awele, A. C. (2021). A comparative study of regulatory systems and quality management practices in the manufacturing process of different pharmaceutical companies in Nigeria.
5. Diaz, A., Baweja, R., Bonatakis, J. K., & Baweja, R. (2021). Global health disparities in vulnerable populations of psychiatric patients during the COVID-19 pandemic. World Journal of Psychiatry, 11(4), 94.
6. Glover, B., Akinbo, O., Savadogo, M., Timpo, S., Lemgo, G., Sinebo, W., Akile, S., Obukosia, S., Ouedraogo, J., Ndomondo-Sigonda, M., & Koch, M. (2018, July). Strengthening regulatory capacity for gene drives in Africa: Leveraging NEPAD's experience in establishing regulatory systems for medicines and GM crops in Africa. In BMC Proceedings (Vol. 12, No. 8, 19-28). BioMed Central.
7. Haji, S. K. (2023). Poor accountability and corruption and its impact on quality of care in the public health sector within the Kurdistan Region of Iraq (Doctoral dissertation, University of Portsmouth).
8. Liu, X., Barenji, A. V., Li, Z., Montreuil, B., & Huang, G. Q. (2021). Blockchain-based smart tracking and tracing platform for drug supply chain. Computers & Industrial Engineering, 161, 107669.
9. Ncube, B. M., Dube, A., & Ward, K. (2021). Establishment of the African Medicines Agency: Progress, challenges and regulatory readiness. Journal of Pharmaceutical Policy and Practice, 14, 1-12.
10. Ndomondo-Sigonda, M., Miot, J., Naidoo, S., Dodoo, A., & Kaale, E. (2017). Medicines regulation in Africa: Current state and opportunities. Pharmaceutical Medicine, 31, 383-397.
11. Nigeria's, I. W. (2023). Chapter five interaction within Nigeria's pharmaceutical industry Adesina Ayobami Oyewale. Domestic Production and Procurement of Medicines in Nigeria: Capabilities, Challenges and Prospects, 47.
12. Roth, L., Bempong, D., Babigumira, J.B., Banoo, S., Cooke, E., Jeffreys, D., Kasonde, L., Leufkens, H.G., Lim, J.C., Lumpkin, M., & Mahlangu, G. (2018). Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems. Globalization and Health, 14(1), 1-12.
13. Sunny, J., Undralla, N., & Pillai, V.M. (2020). Supply chain transparency through blockchain-based traceability: An overview with demonstration. Computers & Industrial Engineering, 150, 106895.

14. World Health Organization. (2017). WHO Global Surveillance and Monitoring System for substandard and falsified medical products.
15. Beccaria, M., & Cabooter, D. (2020). Current developments in LC-MS for pharmaceutical analysis. Analyst, 145(4), 1129-1157. https://doi.org/10.1039/C9AN02294E
16. Beng, H., Hu, J., Zhang, R., Huang, Y., Chen, X., & Tan, W. (2021). Quantitative DESI mass spectrometry imaging of lung distribution of inhaled drug. Journal of Drug Delivery Science and Technology, 66, 102794. https://doi.org/10.1016/j.jddst.2021.102794
17. Bobaly, B., Lauber, M., Beck, A., Guillarme, D., & Fekete, S. (2018). Utility of a high coverage phenyl-bonding and wide-pore superficially porous particle for the analysis of monoclonal antibodies and related products. Journal of Chromatography A, 1540, 63-76. https://doi.org/10.1016/j.chroma.2018.01.044
18. Bobaly, R., D'Atri, V., Lauber, M., Beck, A., Guillarme, D., & Fekete, S. (2018). Characterizing various monoclonal antibodies with milder reversed phase chromatography conditions. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 1000, 1-10. https://doi.org/10.1016/j.jchromb.2017.11.020
19. Camperi, J., Dai, L., Guillarme, D., & Stella, C. (2020). Fast and automated characterization of monoclonal antibody minor variants from cell cultures by combined protein-A and multidimensional LC/MS methodologies. Analytical Chemistry, 92(12), 8506-8513. https://doi.org/10.1021/acs.analchem.0c01359
20. Camperi, J., Guillarme, D., Lei, M., & Stella, C. (2020). Automated middle-up approach for the characterization of biotherapeutic products by combining on-line hinge-specific digestion with RPLC-HRMS analysis. Journal of Pharmaceutical and Biomedical Analysis, 182, 113130. https://doi.org/10.1016/j.jpba.2020.113130
21. Camperi, J., Guillarme, D., & Stella, C. (2021). Multi-dimensional LC-MS: The next generation characterization of antibody-based therapeutics by unified online bottom-up, middle-up, and intact approaches. Analyst, 146(3), 747-769. https://doi.org/10.1039/D0AN02182G
22. Carrara, S. C., Ulitzka, M., Grzeschik, I., Kornmann, H., Hock, H., & Kolmar, H. (2021). From cell line development to the formulated drug product: The art of manufacturing therapeutic monoclonal antibodies. International Journal of Pharmaceutics, 594, 120164.
23. Chen, B., Lin, Z., Alpert, A. J., Fu, C., Zhan, Q., Pritts, W. A., & Ge, Y. (2018). Online hydrophobic interaction chromatography-mass spectrometry for the analysis of intact monoclonal antibodies. Analytical Chemistry, 90(12), 7135–7138.
24. Chen, Y., Li, J., & Schmitz, O. J. (2019). Development of an at-column dilution modulator for flexible and precise control of dilution factors to overcome mobile phase incompatibility in comprehensive two-dimensional liquid chromatography. Analytical Chemistry, 92(15), 10251–10257.
25. Comamala, G., Wagner, C., de la Torre, P. S., Jakobsen, R. U., Hilger, M., Brouwer, H.-J., & Rand, K. D. (2020). Hydrogen/deuterium exchange mass spectrometry with improved electrochemical reduction enables comprehensive epitope mapping of a therapeutic antibody to the cysteine-

knot containing vascular endothelial growth factor. Analytica Chimica Acta, 1115, 41–51.
26. Cortese, M., Gigliobianco, M. R., Magnoni, F., Censi, R., & Di Martino, P. (2020). Compensate for or minimize matrix effects? Strategies for overcoming matrix effects in liquid chromatography-mass spectrometry technique: A tutorial review. Molecules, 25(13), 3047.
27. D'Atri, V., Causon, T., Hernandez-Alba, O., Mutabazi, A., Veuthey, J.-L., Cianferani, S., & Guillarme, D. (2018). Adding a new separation dimension to M5 and LC-MS: What is the utility of ion mobility spectrometry? Journal of Separation Science, 47(1), 20–67.
28. Devine, P. W. A., Fisher, H. C., Calabrese, A. N., Whelan, F., Higazi, D. R., Potts, J. R., Lowe, D. C., Radford, S. E., & Ashcroft, A. E. (2017). Investigating the structural compaction of biomolecules upon transition to the gas-phase using ESI-TWIMS MS. Journal of The American Society for Mass Spectrometry, 28(9), 1855-1862. https://doi.org/10.1007/s13361-017-1642-3
29. Dubbelman, A.-C., Cuyckens, F., Dillen, L., Gross, G., Vrecken, R., Hankemeier, T. (2018). Mass spectrometric recommendations for Quan/Qual analysis using liquid-chromatography coupled to quadrupole time-of-flight mass spectrometry. Analytica Chimica Acta, 102062, 1-75. https://doi.org/10.1016/j.aca.2018.10.019
30. Duerr, C., & Fries, W. (2019). Antibody-drug conjugates stability and formulation. European Journal of Pharmaceutics and Biopharmaceutics, 130, 168-176. https://doi.org/10.1016/j.ejpb.2018.11.016
31. Dunn, Z. D., Desai, J., Leme, G. M., Stoll, D. R., & Richardson, D. D. (2020). Rapid two-dimensional protein A size exclusion chromatography of monoclonal antibodies for titer and aggregation measurements from harvested cell culture fluid samples. mALn, 12(1), 1702263. https://doi.org/10.1021/acsm.9b02455
32. Eckard, A. D., Dupont, R. D., & Young, J. K. (2018). Development of two analytical methods based on reverse phase chromatographic and SDS-PAGE gel for assessment of deglycosylation yield in N-glycan mapping. BioMed Research International, 3909674. https://doi.org/10.1155/2018/3909674
33. Ehkirch, A., D'Atri, V., Rouviere, F., Hernandez-Alba, O., Goyun, A., Sarrut, M., Beck, A., Guillarme, D., Heinisch, S., & Cianferani, S. (2018). An online four-dimensional HIC SEC IMXMS methodology for proof-of-concept characterization of antibody-drug conjugates. Analytical Chemistry, 90(3), 1578-1586. https://doi.org/10.1021/acs.analchem.7b04287
34. Ehkirch, A., Goyon, A., Hernandez Alba, O., Rouviere, F., D'Atri, V., Dreyfus, C., Haeuw, J.-F., Diemer, H., Beck, A., Heinisch, S., Guillarme, D., & Cianferani, S. (2018). A novel online four-dimensional SECXSEC-IMAMS methodology for characterization of monoclonal antibody size variants. Analytical Chemistry, 90(23), 13929-13937. https://doi.org/10.1021/acs.analchem.8b02701
35. Ehkirch, A., Hernandez Alba, O., Colas, O., Beck, A., Guillarme, D., & Cianferani, S. (2018). Hyphenation of size exclusion chromatography to native ion mobility mass spectrometry for the analytical characterization of therapeutic antibodies and related products. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 1086, 176-183. https://doi.org/10.1016/j.jchromb.2018.06.003

36. European Medicines Agency. (2017). Guideline on clinical development of fixed combination medicinal products, EMA/CHMP/158268/2017. Retrieved from http://www.ema.europa.eu/ema/
37. Fasert, K., Sarg, B., Maurer, V., & Lindner, H. H. (2017). Exploiting charge differences for the analysis of challenging post-translational modifications by capillary electrophoresis-mass spectrometry. Journal of Chromatography A, 2498, 215-223. https://doi.org/10.1016/j.chroma.2017.09.061
38. Focosi, D., McConnell, S., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022). Monoclonal antibody therapies against SARS-CoV-2. The Lancet Infectious Diseases, 22(11), 311-326. https://doi.org/10.1016/S1473-3099(22)00276-2
39. Fussl, F., Strasser, L., Carillo, S., & Bones, J. (2021). Native LC-MS for capturing quality attributes of biopharmaceuticals on the intact protein level. Current Opinion in Biotechnology, 71, 32-40. https://doi.org/10.1016/j.copbio.2021.06.001
40. Gandhi, A. V., Pothecary, M. R., Bain, D. L., & Carpenter, J. F. (2017). Some lessons learned from a comparison between sedimentation velocity analytical ultracentrifugation and size exclusion chromatography to characterize and quantify protein aggregates. Journal of Pharmaceutical Sciences, 106(8), 2178-2181. https://doi.org/10.1016/j.xphs.2017.04.004
41. Goyon, A., Beck, A., Colas, O., Sandra, K., & Guillarme, D. (2017). Evaluation of size exclusion chromatography columns packed with sub-3 µm particles for the analysis of biopharmaceutical proteins. Journal of Chromatography A, 1498, 80-89. https://doi.org/10.1016/j.chroma.2017.03.050
42. Goyon, A., D'Atri, V., Colas, O., Fekete, S., Beck, A., & Guillarme, D. (2017). Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry hyphenation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1065, 35-43. https://doi.org/10.1016/j.jchromb.2017.08.013
43. Gstuttner, C., Vergoossen, D. L. E., Wuhrer, M., Huijbers, M. G. M., Dominguez-Vega, E. (2021). Sheathless CE-MS as a tool for monitoring exchange efficiency and stability of bispecific antibodies. Electrophoresis, 42(1-2), 171-176. https://doi.org/10.1002/elps.202100110
44. Hong, A., Lee, H. H., Heo, C. E., Cho, Y., Kim, S., Kung, D., Kim, H. I. (2017). Distinct fragmentation pathways of anticancer drugs induced by charge-carrying cations in the gas phase. Journal of the American Society for Mass Spectrometry, 28(4), 628-637. https://doi.org/10.1007/s13361-017-1617-z
45. Khalikova, M. (2019). N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. European Journal of Pharmaceutics and Biopharmaceutics, 139, 123-131. https://doi.org/10.1016/j.ejpb.2019.04.010
46. Hanko, V. P., Rohrer, S. (2020). Determination of amino acids in cell culture and fermentation broth media using anion-exchange chromatography with integrated pulsed amperometric detection. Analytical Biochemistry, 324(1), 29-38. https://doi.org/10.1016/j.ab.2003.12.001
47. International Conference on Harmonization. (2019). ICH guideline M10 on bioanalytical method validation and study sample analysis. International Conference on Harmonization of Technical Requirements for Registration of

Pharmaceuticals for Human Use. Retrieved from https://www.ich.org/page/m10-bioanalytical-method-validation
48. International Council for Harmonization (ICH) Guideline: M7 (R1) Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. (2018b).
49. Jukes, C., Fusal, F., Zaborowska, I., & Bones, J. (2021). Rapid analysis of biotherapeutics using protein A chromatography coupled to orbitrap mass spectrometry. Analytical Chemistry, 93(40), 13505-13512.
50. Kaltashov, L. A., Bobst, C. E., Pawłowski, I., & Wang, G. (2020). Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics. Journal of Pharmaceutical and Biomedical Analysis, 184, 113169.
51. Kashimura, A., Tanaka, K., Sato, H., Kaji, H., & Tanaka, M. (2018). Imaging mass spectrometry for toxicity assessment: A useful technique to confirm drug distribution in histologically confirmed lesions. Journal of Toxicologic Pathology, 31(3), 221-227.
52. Kaur, H. (2021a). Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Critical Reviews in Biotechnology, 41(2), 300-315.
53. Kaur, H. (2021b). Capillary electrophoresis and the biopharmaceutical industry: Therapeutic protein analysis and characterization. Trends in Analytical Chemistry, 144, 116407.

دور المختبرات الصيدلانية في تطوير الأدوية ومراقبة الجودة

الملخص
الخلفية: للمختبرات الصيدلانية أهمية اجتماعية كبيرة، حيث تقوم بدور أساسي في تطوير الأدوية وضمان توافقها مع معايير الجودة لتحسين حالة المرضى.
الهدف: تهدف هذه الدراسة إلى تسليط الضوء على التقنيات التحليلية والابتكارات، بالإضافة إلى مراقبة الجودة في تطوير الأدوية والمختبرات الصيدلانية.
الطرق: هناك حاجة لإجراء مراجعة أدبية ودراسات سابقة لتحديد مراحل تطوير الأدوية، والتحليل قبل السريري، وكذلك مراقبة الجودة.
النتائج: تعمل المختبرات على تحسين فعالية الأدوية من خلال آليات الجودة، والتقدم في التكنولوجيا، واتخاذ التدابير القانونية الأخرى.
الاستنتاج: تلعب المختبرات الصيدلانية دورًا محوريًا في تسهيل إنتاج أدوية آمنة وفعّالة، بالإضافة إلى التوقعات المستقبلية في تطور الطب.
الكلمات المفتاحية: علم الأدوية، الرعاية المدارة، إنتاج الأدوية واختبارها، المنهجيات التحليلية، تقدم الأدوية.